Physician profile
Anu Roop Mongia
NPI 1659332922
$8,096.61
in general payments reported to CMS, 2019-2025
37 companies · $1,113 in 2025
The $1,113 reported for 2025 was less than what a typical Allergy provider received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,502 · 2020: $482 · 2021: $689 · 2022: $965 · 2023: $1,402 · 2024: $944 · 2025: $1,113.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,347 · Education: $89.09 · Consulting Fee: $22.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,347.14 |
| Education | $89.09 |
| Consulting Fee | $22.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $1,797.25 | 2019-2024 | Nuzyra |
| Genzyme Corporation | $1,007.89 | 2019-2025 | |
| Glaxosmithkline, LLC. | $915.25 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $863.61 | 2019-2025 | Fasenra, Airsupra |
| Regeneron Healthcare Solutions, INC. | $466.20 | 2019-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $435.47 | 2021-2025 | Cuvitru, Glassia |
| Grifols USA, LLC | $291.48 | 2020-2025 | Xembify |
| Csl Behring | $212.33 | 2019-2025 | Andembry, Haegarda, Hizentra |
| Novartis Pharmaceuticals Corporation | $202.12 | 2023-2025 | |
| Biocryst US Sales Co., LLC | $195.61 | 2021-2025 | Orladeyo |
| Pfizer INC. | $174.88 | 2021-2025 | |
| Octapharma USA, INC. | $173.89 | 2019-2024 | Cutaquig |
| Optinose US, INC. | $153.49 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $148.15 | 2019-2022 | |
| Amgen INC. | $129.32 | 2022-2025 | Tezspire |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $125.00 | 2025 | Auvelity |
| Ionis Pharmaceuticals, INC. | $88.50 | 2025 | Dawnzera |
| Abbvie INC. | $69.11 | 2021-2024 | |
| Astellas Pharma US INC | $67.74 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $65.37 | 2021-2022 | |
| Kaleo, INC. | $61.42 | 2020-2022 | |
| Aimmune Therapeutics, INC. | $47.06 | 2021-2022 | |
| Pharming Healthcare, INC. | $39.92 | 2019-2020 | |
| Adma Biomanufacturing LLC | $38.69 | 2022-2023 | |
| Shire North American Group INC | $38.35 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $37.87 | 2023-2025 | Vibativ |
| Alk-Abello, INC | $36.60 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $34.90 | 2021 | |
| Circassia INC. | $33.02 | 2019 | |
| Genentech USA, INC. | $30.69 | 2019-2021 | |
| Viiv Healthcare Company | $19.13 | 2020 | |
| Biocryst Pharmaceuticals, INC. | $18.59 | 2020 | |
| La Jolla Pharmaceutical Company | $16.88 | 2025 | Zevtera |
| Ars Pharmaceuticals Operations, INC. | $16.36 | 2025 | Neffy |
| Uswm, LLC | $16.00 | 2021 | |
| Theratechnologies INC. | $15.76 | 2020 | |
| Phadia US INC. | $12.71 | 2023 | Immunocap |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anu Mongia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.